EDMONTON, ALBERTA--(Marketwire - August 18, 2008) - ViRexx Medical Corp. (TSX: VIR) (AMEX: REX), company focused on developing innovative-targeted therapeutic products that offer better quality of life and a renewed hope for living. Its platform technologies include product candidates for the treatment of Hepatitis B, Hepatitis C, avian influenza viral infections, biodefence and nanoparticle applications, select solid tumors and late-stage ovarian cancer, today announced that it is presenting encouraging results from the laboratory studies on its lead Chimigen™ Hepatitis B Therapeutic Vaccine candidate.
